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Background: Cachexia is the widespread loss of muscle and fat that causes death in many cancers.
Results: Secretion of leukemia inhibitory factor (LIF) by C26 cancer cells activates differential gene expression that results in
muscle cell atrophy.
Conclusion: LIF produced by cancer cells acts on muscle to cause atrophy.
Significance: LIF and its signaling pathway are new targets in fighting cancer cachexia.
Cachexia is an exacerbating event inmany types of cancer that
is strongly associated with a poor prognosis. We have identified
cytokine, signaling, and transcription factors that are required
for cachexia in themouseC26 colon carcinomamodel of cancer.
C2C12 myotubes treated with conditioned medium from C26
cancer cells induced atrophy and activated a STAT-dependent
reporter gene but not reporter genes dependent on SMAD,
FOXO, C/EBP, NF-B, or AP-1. Of the gp130 family members
IL-11, IL-6, oncostatinM (OSM), and leukemia inhibitory factor
(LIF), only OSM and LIF were sufficient to activate the STAT
reporter in myotubes. LIF was elevated in C26 conditioned
medium (CM), but IL-6,OSM,TNF, andmyostatinwere not.A
LIF-blocking antibody abolished C26 CM-induced STAT
reporter activation, STAT3 phosphorylation, and myotube
atrophy but blocking antibodies to IL-6 or OSM did not. JAK2
inhibitors also blocked C26 CM-induced STAT reporter activa-
tion, STAT3 phosphorylation, and atrophy in myotubes. LIF at
levels found in the C26 CM was sufficient for STAT reporter
activation and atrophy in myotubes. In vivo, an increase in
serum LIF preceded the increase in IL-6 in mice with C26
tumors. Overexpression of a dominant negative Stat3C-EGFP
gene in myotubes and in mouse muscle blocked the atrophy
caused by C26 CMor C26 tumors, respectively. Taken together,
these data support an important role of LIF-JAK2-STAT3 in
C26 cachexia and point to a therapeutic approach for at least
some types of cancer cachexia.
Cancer cachexia is the systematic loss of body weight that
cannot be reversed by diet and is a burden often determining
the prognosis of the disease. In up to 30% of all cancers it leads
to death through a combination of extreme weakness,
decreased resistance to infection, and the inability to tolerate
needed therapy (1–3). Cachexia is especially prevalent in can-
cers of the colon, lung, and pancreas and involves a significant
loss of both fat stores andmuscle mass throughout the body (1,
4). To study cancer cachexia, animal tumor models have been
used as systems in which the factors responsible formuscle and
adipose loss can be isolated and tested more easily than in can-
cer patients. One of the most studied models is C26 colon ade-
nocarcinoma in mice (5–7). Several different transcription fac-
tors, signaling pathways, and triggering ligands have been
implicated in C26-induced skeletal muscle atrophy. In particu-
lar, there is evidence that the JAK/STAT, SMAD, FOXO, and
ERK families are involved inmuscle wasting during C26 cancer
cachexia (8–13), and the cytokines most commonly linked to
muscle atrophy from C26 tumors include IL-6 and myostatin
(10, 12, 14). However, our understanding of the cell biology
underlying cachexia is still in its early stages.
In thiswork,we identified a key cytokine and its signaling and
transcription factor pathways responsible for C26 cancer
cachexia. AC26 conditionedmedium (CM)2model was used to
identify the cytokines secreted and the signaling and transcrip-
tion factors activated by C26 tumor cells that producemyotube
atrophy. The main observations were confirmed in mice with
C26 tumors. We found that JAK/STAT (8, 12) and ERK (11)
signaling was stimulated by CM from C26 tumor cells. More-
over, we show that leukemia inhibitory factor (LIF) is the cyto-
kine inducing both JAK2/STAT3 and ERK signaling as well as
atrophy in myotubes treated with medium from C26 cancer
cells. This is the first direct evidence that LIF is an essential
regulator of cachexia from C26 tumors.
Experimental Procedures
Biochemicals—The cytokines used were as follows: mouse
IL-11,mouseOSM,mouse IL-6, andmyostatin were fromR&D
Systems (Minneapolis, MN). Mouse LIF was from eBioscience
(San Diego, CA). Blocking antibodies for LIF and OSM were
obtained from R&D Systems, and blocking antibody for IL-6
was obtained from eBioscience. When antibodies were used to
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block cytokine activity, normal IgG of the same species as the
blocking antibody was added to controls. The inhibitors used
were ruxolitinib/INCB-18424 (ChemieTek, Indianapolis IN),
JAK2 inhibitors, Tyrphostin AG490 andWP1066 (Sigma), and
the ERK 1/2 inhibitor U0126 (EMD/Millipore, Danvers MA).
When inhibitors required dimethyl sulfoxide (anhydrous, Life
Technologies) for solubility then controls had dimethyl sulfox-
ide added at the same level as in the inhibitor solutions.
ELISA—ELISAs for LIF, myostatin, and OSM were from
R&D Systems. ELISAs for TNF and IL-6 were from eBiosci-
ence. All ELISAs were performed according to the protocols of
the manufacturers.
Plasmids—To create a dominant negative STAT, we took the
plasmid pMXs-Stat3-C (Addgene plasmid 13373) (15) and
removed theC-terminal transactivation domain as described in
Ref. 16. We then subcloned Stat3C into the EGFP-N1 plas-
mid to create our designation d.n.STAT3C-EGFPN1
(d.n.STAT3), which was sequenced (GeneWiz, Cambridge
MA) to confirm the in-frame sequence of the fusion construct.
The plasmids pPIAS1 and pPIAS3 were bought from Addgene
(plasmids 15206 and 15207) (17). The STAT reporter plasmid
STAT-luc (plasmid 8688) and the SMAD reporter plasmid
SMAD-luc (plasmid 16495) were from Addgene (Cambridge,
MA). The NF-B and AP-1 reporters have been described pre-
viously (18). The C/EBP reporter was purchased from Signosis
(Santa Clara, CA). The FOXO-luc reporter was obtained from
the Greenberg laboratory and has been described previously
(19). All plasmids were prepared using Qiagen Maxi or Mega
endotoxin removal kits and stored at 20 °C in Tris-EDTA
until used.
Cell Culture and Transfection—C26 adenocarcinoma cells
obtained from the National Cancer Institute (Frederick, MD)
were plated andmaintained as described previously (8). C2C12
myoblasts were purchased from the ATCC and used within the
first 15 passages. C2C12 cells were cultured in DMEM/10%
FBS, passed at least every 2 days, and differentiated in
DMEM/2% horse serum (HS) for 4 days. Transfections were
done on C2C12 myoblasts using Effectene (Qiagen, Valencia,
CA) for reporter assays and GeneCellin (Bulldog Bio, Ports-
mouth, NH) for transfections when myotube diameters were
measured, with the following details. For Effectene, myoblasts
were seeded in growth medium at 5  104 cells/well on a
24-well plate the night before transfection in growth medium.
12–16 h later, DNA (0.5 g/well)-Effectene mixes were added
to the cells in differentiation medium. For GeneCellin, cells
were seeded in growthmedium at 5 105 cells/well on a 6-well
plate and allowed to attach overnight. The next day, cells were
switched to differentiation medium and transfected with 2 g
of DNA/well for a 6-well plate using GeneCellin transfection
reagent. The medium was refreshed 24 h later.
CM Collection—Conditioned medium for C26 cells was
made using the method of Lokireddy et al. (10). C26 cells and
C2C12 myoblasts were grown in 5% FBS or 10% FBS, respec-
tively, at 37 °C in 5% CO2. When the plates reached a conflu-
ency of90%, the growth medium was removed, and the cells
were washed twice with sterile PBS and three times with
DMEM with no serum plus antibiotics and glutamine. It was
found to be important that conditioned medium was taken
from the cells in medium without serum. Fetal bovine serum
contains myostatin (see below) and induces C26 cells to pro-
duce IL-6 at a level 50-fold higher than when it is not present.
C26 cells were grown in DMEM plus antibiotics and glutamine
with no serum for 24 h. After 24 h, the medium was collected
and centrifuged in 50-ml Falcon tubes at 4500 rpm for 15min at
4 °C. The supernatant was filtered through a 0.22-micron filter
in a sterile environment. Aliquots of the filtered medium were
stored at 80 °C for up to a year. Conditioned medium treat-
mentwas 33%CM in differentiationmedium (2%HS inDMEM
plus antibiotics and glutamine). Treatment for controls was
33% DMEM plus antibiotics and glutamine without serum.
Luciferase Reporter Assays—C2C12 myoblasts in growth
serum were plated on a 24-well plate at a density of 5  104
cells/well and left overnight for attachment. Cells were then
switched to differentiationmedium and transfectedwith 0.5g
of a luciferase reporter plasmid and 0.05 g of EGFP/well. The
differentiation medium was changed 24 h later, and was EGFP
visualized for transfection efficiency. Cells were treated 4 days
post-transfection, lysed with 200 l of passive lysis buffer (Pro-
mega, Madison, WI), and luciferase activity was measured as
detailed previously (20).
Immunoblotting—The antibodies for Western blots were
anti-phospho-STAT3 (Tyr-705, catalog no. 9139), anti-STAT3
(catalog no. 9139), anti-phospho-STAT1 (Tyr-701, catalog no.
7649), anti-STAT1 (catalog no. 9172), anti-phospho-STAT5
(Tyr-694, catalog no. 4322), anti-STAT5 (catalog no. 9363),
anti-pERK1/2 (Thr-202/Tyr-204, catalog no. 4370), anti
ERK1/2 (catalog no. 4695) (Cell Signaling, Danvers, MA), anti-
myostatin (catalog no. AF788, R&D Systems), and anti-
GAPDH (Sigma). Myotubes were lysed with 1 radioimmune
precipitation assay buffer (Cell Signaling Technology) and 1
mM PMSF. The protein concentration of cell lysates was mea-
sured using the Bio-Rad DC assay (Bio-Rad). Equal amounts of
protein from each sample were separated by electrophoresis,
transferred to a membrane, and incubated with primary and
secondary antibodies as detailed previously (21). Protein signals
were visualized using indirect immunostaining with infrared
fluorescence imaging using a LiCor Odyssey imager.
Myotube Diameter Studies—For phase and fluorescence
micrographs of C2C12 myotubes, cultures were treated with
differentiation medium supplemented with 33% DMEM (con-
trol) or 33%C26CM for 48 h beginning at 3 d of differentiation.
The myotubes were photographed and measured as detailed
previously (20). When needed, differentiated myotubes were
visualized with MF20, a sarcomeric myosin-specific antibody
from Developmental Studies Hybridoma Bank (University of
Iowa), followed by incubation with a secondary antibody con-
jugated to Alexa Fluor 488 (Life Technologies).
Gene Expression Studies—Total RNAwas isolated frommyo-
tubes treated with LIF for 4, 8, or 24 h and from vehicle-treated
(PBS) myotubes at each time point. Each of these six groups
contained three independent samples. Total RNAwas isolated
using the miRNeasy mini kit (Qiagen), and quantity and
quality were measured by NanoDrop spectroscopy and Agi-
lent Bioanalyzer assay. The Boston University Microarray
Resource Core Facility performed first-strand synthesis and
hybridization to Affymetrix mouse 1.0 ST arrays. For
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microarray studies, the RNA samples in each of the six
groups were pooled. For quantitative real-time PCR, RNA
samples were converted to cDNA with the Qiagen Quanti-
Tect kit, followed by real-time quantitative PCR on an ABI
7300 thermal cycler using Fast Advanced Master Mix and
TaqMan primer-probe sets purchased from Life Technolo-
gies. The probe sets were as follows: Mm00545913_s1,
Socs3; Mm00504306_m1, Bcl-3; Mm00786711_s1, CEBP;
Mm01275601_g1, Bnip3; Mm00432307_m1, Casp4;
Mm01197698_m1, Gusb; and Mm01545399_m1, Hprt.
Animals—Mice with C26 tumors were prepared as described
previously (21). Eight-week-old male CDF1 mice purchased
from Charles River Laboratories (Wilmington, MA) were used
for all experiments. This study was carried out in strict accord-
ancewith the recommendations given in theUnited States Pub-
lic Health Service Policy on Humane Care and Use of Labora-
tory Animals. The protocol was approved by the Boston
University Institutional Animal Care and Use Committee (pro-
tocol number 12–016).
Plasmids were prepared and injected into mouse tibialis
anterior (TA) muscles 14 days after C26 tumor cell inocula-
tions, as detailed previously (21). On day 25 post-inoculation,
TA muscles were removed from control and C26 tumor-bear-
ing mice and prepared for analysis. The myofiber cross-sec-
tional areawasmeasured as detailed previously (21). TAmuscle
fiber cross-sectional areas of plasmid-transfected fibers (green)
were compared with fiber areas in the same fields that did not
take up the plasmid (black) in both tumor-bearing and control
mice. Laminin was stained with an antibody coupled to Texas
Red-X to demarcate the muscle fiber membranes.
Statistics—For one variable analysis, an unpaired Student’s t
test was used to determine significant difference. Formultivari-
able analysis, a one-way analysis of variance with Tukey’s post
test was used. Data are expressed asmean S.E., and statistical
difference was defined at p 0.05.
Results
Characterization of a C26 CMMyotube Atrophy Model—To
focus on the factors that trigger muscle wasting in C26 mouse
colon carcinoma, we used medium from C26 cells and treated
cultured myotubes. First, we isolated C26 CM to verify that it
produced atrophy, as measured by decreased myotube diame-
ters of differentiated C2C12 myotubes (Fig. 1A). A 15%
decrease in myotube diameter could be seen as early as 24 h
after addition of the C26 CM, and there was a 20% decrease in
diameter at 48 h (Fig. 1B).
STAT-dependent Transcriptional Activation in C26 CM-
treatedMyotubes Is Mediated by LIF—To test a role for several
transcription factors as expediently as possible in CM-treated
myotubes,we transfecteda series of transcription factor-depen-
dent reporter genes into myoblasts, differentiated the cultures
to myotubes, and surveyed them for inducibility by C26 CM
(Fig. 1C). Despite several transcription factors being implicated
in different types of cancer cachexia in the literature, including
AP-1 (2), C/EBP (22), FOXO (10, 13), NF-B (10, 23), SMAD
2/3 (10), and STAT3 (8, 12), our survey of reporters showed that
only the STAT reporter was activated by C26 CM (Fig. 1C).
Although data for 4 h are shown, reporters dependent on the
other transcription factors did not respond to CM at any time
over a 24-h timeperiod (data not shown).A time course showed
FIGURE 1.Atrophy andSTAT reporter activation in theC26CMmodel of cancer cachexia.A, C2C12myotubes treated for 24 hwith control or 33%C26CM,
stained with an antibody to sarcomeric myosin, and visualized by immunofluorescence. B, time course of C2C12 myotube diameter after 0, 24, and 48 h of
treatmentwith C26 CM. C, luciferase activity of reporters in C2C12myotubes treated for 4 hwith C26 CM.D, time course of STAT reporter induction by C26 CM
compared with control from 0–24 h for a single dose of C26 CM added to C2C12 myotubes at time 0. *, p 0.05 compared with control value.
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that the STAT reporter was activated significantly by 1 h after
C26 CM addition, peaked at 2 h after CM addition, and contin-
ued to be elevated for 8 h (Fig. 1D).
We next tested the source of STAT induction in the C26 CM
by treatingC2C12myotubeswith a battery of cytokines that are
active in the JAK/STAT pathway and that have been found in
the serum of C26 cachecticmice (6, 8, 9).We added 10 ng/ml of
IL-11, IL-6,OSM, or LIF to themyotubes and assayed for STAT
reporter activity (Fig. 2A). OSM and LIF were able to markedly
induce the STAT reporter, whereas IL-6 had a smaller effect.
To test whether these cytokines were responsible for CM-in-
duced STAT reporter activation in myotubes, blocking anti-
bodies were added to the myotubes treated with C26 CM (Fig.
2, B–D). The results show that the antibodies were effective
against their particular ligands, but only the antibody to LIF
could block the STAT reporter activity induced by C26 CM.
We recently showed that an antibody to IL-6 blocks myotube
atrophy because of IL-6 treatment (10 ng/ml), indicating the
effectiveness of this antibody (20). However, C26 CM-induced
STAT activation could not be blocked by the same IL-6-block-
ing antibody (Fig. 2D).
LIF Is the Active Cytokine Causing Myotube Atrophy by C26
CMTreatment—We assayed C26 CM for levels of LIF and sev-
eral other cytokines that could be inducing atrophy in ourmyo-
tube model (Fig. 3A). TNF or myostatin was not detected in
C26 CM, as measured by ELISA. Also, myostatin was not
detected in C26 CM, as measured by Western blot (Fig. 3B).
The IL-6 concentration in C26 CM was 7 pg/ml, and this was
not significantly different from the levels in C2C12 CM (Fig.
3A). The OSM concentration in C26 CM was350 pg/ml, but
this was not different from levels in C2C12 CM. LIF was ele-
vated significantly in C26 CM compared with undetectable lev-
els in C2C12 CM (Fig. 3A). LIF was sufficient to induce atrophy
when tested at the C26 CM level of 370 pg/ml (Fig. 3C). More-
over, the blocking antibody to LIF completely blocked themyo-
tube atrophy induced by the C26 CM (Fig. 3D). Although not
elevated in C26 CM, high levels of IL-6 (10 or 100 ng/ml) are
sufficient to induce atrophy in cultured myotubes, as we and
others have shown (12, 20). However, a blocking antibody to
IL-6 did not reverse C26 CM-induced atrophy (Fig. 3E).
STAT1, STAT3, and STAT5—Because the STAT reporter
was instrumental in leading our investigation into the signaling
of C26 cachexia, we next studied the involvement of two major
STATs. The activation of STAT is known to be due to specific
phosphorylation (24), and so we investigated the phosphoryla-
tion of STAT3 and STAT1 by C26 CM and LIF. The time
course for the appearance of pSTAT3 (Fig. 4A) and pSTAT1
(Fig. 4B) when C2C12 myotubes were treated with C26 CM or
withLIF showed the following.There is a strongphosphorylation
of STAT3and aweaker but significant phosphorylation of STAT1
at the same time, peaking at 30 min after addition of either C26
CM or LIF. This precedes the peak for the time course of STAT
reporter activation by C26 CM, as shown in Fig. 1.
We inhibited C26 CM-induced STAT activation and myo-
tube atrophy using variousmethods.Ablocking antibody to LIF
inhibited C26 CM-induced STAT3 phosphorylation but not
CM-induced STAT1 phosphorylation (Fig. 4C). We then used
two naturally occurring protein inhibitors of active STAT1 and
STAT3, PIAS1 and PIAS3 (17), respectively, to elucidate which
STATmight bemore responsible for STAT reporter activation
in CM-treated myotubes. Overexpression of PIAS1 was unable
to inhibit C26 CM-induced STAT reporter activation (Fig. 4D).
On the other hand, PIAS3 overexpression inhibited 50% of
STAT reporter activation (Fig. 4D). We also used another
genetic method to inhibit STAT3 by creating a dominant neg-
ative STAT3 (d.n.STAT3). We took a constitutive dimer-pro-
ducing version of STAT3 (26) and removed the C-terminal
transactivation domain, effectively creating the beta form (16).
This new molecule forms dimers and binds to all STAT3
response elements but is not able to activate them. In addition,
we added EGFP to the C terminus to visualize this molecule
in cells. In C2C12 myotubes, our d.n.STAT3C-EGFPN1
(d.n.STAT3) inhibited C26 CM and LIF-induced STAT
reporter activation by 50% (Fig. 4E), similar to the inhibition by
PIAS3. Because STAT reporter activation was not affected by
STAT1 inhibition and was reversed by 50% with STAT3 inhi-
bition, we studied another STAT and measured the expression
of STAT5 and pSTAT5. STAT5 was phosphorylated to a simi-
lar extent as STAT1 and STAT3 when treated with C26 CM
(Fig. 4F), although STAT5 is expressed at lower levels in C2C12
myotubes. In addition to the effects on STAT3phosphorylation
and STAT reporter activity, STAT3 was required for CM-in-
duced myotube atrophy because d.n.STAT3 expression
blocked CM-induced atrophy (Fig. 4G).
FIGURE 2. Effect of gp130 family cytokines on STAT reporter activity in
C2C12 myotubes. A, STAT reporter activity of myotubes treated with 10
ng/ml of cytokines for 4 h. B, activation of the STAT reporter bymouse OSM is
reversed by the OSM antibody (Ab), but C26 CM-induced STAT reporter acti-
vation is not reversed by the anti-OSM antibody. C, activation of the STAT
reporter by mouse LIF is inhibited by the LIF antibody, and C26 CM-induced
STAT reporter activity is reversed by the LIF antibody.D, the IL-6 antibody has
no effect on C26 CM-induced STAT activation. *, p  0.05 compared with
untreated control.
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JAK2 Activates the STATs in C26 CM-induced Myotube
Atrophy—The gp130 family of cytokines, including LIF, acti-
vate the STATs by JAK1/2 (24). Therefore, we tested whether
the JAK1/2 inhibitor ruxolitinib (27) could block LIF and C26
CM-induced STAT reporter activation and myotube atrophy
(Fig. 5). Ruxolitinib (3 M) completely blocked the STAT
reporter activation induced by LIF or by C26 CM (Fig. 5A) and
reversed the phosphorylation of STAT3byC26CM(Fig. 5B). In
addition, ruxolitinib blocked the decrease inmyotube diameter
induced by C26 CM (Fig. 5C) or LIF (Fig. 5D). Finally, two
specific JAK2 inhibitors, AG490 and WP1066, produced com-
plete inhibition of C26 CM STAT reporter activation (Fig. 5E).
Therefore, it appears that JAK2 is the predominant STAT
kinase active in this system.
ERK Signaling in C26 CM—The ERK pathway has also been
implicated in C26 cachexia and is a known signaling arm of LIF
(28). Although no reporter system for activated transcription
factors in this pathway was available, we tested U0126, a known
inhibitor of ERK activation by MEK (28). U0126 at 3 M was
able to inhibitmyotube atrophy because of C26CM (Fig. 6A) or
because of LIF (Fig. 6B). The latter was used at the concentra-
tion (370 pg/ml) found in C26 CM. Phosphorylation of ERK1
and ERK2 occurred as early as 15 min after C26 CM addition
(Fig. 6C). On the other hand, the STAT reporter induced by
either LIF or C26 CM was not affected by ERK inhibition (Fig.
6D), and inhibition of JAKby ruxolitinib did not affect the phos-
phorylation of ERK1/2 by C26 CM (data not shown).
LIF and STAT3 in C26 Cancer-induced Muscle Wasting—
We used the d.n.STAT3 plasmid to test whether STAT3 is
required for atrophy in muscle fibers of C26 tumor-bearing
mice (Fig. 7A). In non-tumor-bearing mice, expression of
d.n.STAT3 resulted in 18% hypertrophy in myofiber cross-sec-
tional area, results first reported by Bonetto et al. (12), who used a
different STAT3 mutant plasmid (STAT3 Y705F). In C26 tumor
mice, there was 24% fiber atrophy compared with control mice.
However, C26 tumor mice showed a lack of atrophy in fibers
expressing d.n.STAT3 (Fig. 7A), evidenced by the 30% increase in
fiber size comparedwith fibers not expressing d.n.STAT3 and sig-
nificantly higher than the 18% expected from d.n.STAT3 hyper-
trophy. We verified the overexpression of d.n.STAT3 by fluores-
cencemicroscopy (Fig. 7B) and also byWestern blot analysis from
plasmid-transducedmuscle (Fig. 7C).
Levels of a number of cytokines in the serum frommice with
and without C26 tumors were measured using ELISA. LIF (Fig.
7D) and IL-6 (Fig. 7E) increased with growth of the tumors.
There was a significant increase in LIF compared with control
mice by 19 days post-tumor inoculation (Fig. 7D), whereas IL-6
was only increased significantly at a later time (Fig. 7E). Myo-
FIGURE3.Cytokines inC26CMand their effects onmyotubediameter.A, ELISAof different cytokines inCMofC2C12or C26 cells. OSM is found inbothCMs,
whereas only LIF is increased significantly in C26 CM. B, Western blot of myostatin in differentiation medium (DM), CM, and medium from C2C12 myotubes
exposed to C26 CM (DMEM on C26 cells for 24 h). From the left, the first lane is DMEM alone, the second lane is 33% DMEM and 67% differentiation medium
(DMEM/2% HS), the third lane is C26 CM, and the fourth lane is medium from myotubes treated for 24 h with 33% C26 CM and 67% differentiation medium.
Myostatin is detected only in mediumwith added horse serum. Themyostatin antibody is made against the final 108 amino acids of mousemyostatin, which
has 100% identity to the amino acid sequence of equine myostatin. C, LIF at the concentration in C26 CM (370 pg/ml) decreases myotube diameter at 24 and
48 h.D, C26 CM-inducedmyotube atrophy is reversed by a blocking antibody (Ab) to LIF. E, the time course ofmyotube diameter reduction fromC26 CM is not
affected by treatment with IL-6-blocking antibody. *, p 0.05 compared with control value.
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statin was quite high in normal mouse serum, as shown previ-
ously (29), and was decreased at later times in C26 tumor-bear-
ing mice during cachexia (Fig. 7F). We did not detect serum
TNF (data not shown), consistent with what was reported by
Strassmann et al. (14).
LIF can induce IL-6 secretion from muscle because, when
C26 CMwas added to C2C12myotubes, IL-6 was elevated (Fig.
7G). This C26 CM-induced IL-6 secretion was inhibited by an
antibody toLIF.However, the levelsof IL-6producedbymyotubes
in response to C26 CM treatment are not high enough to partici-
pate in atrophy because an antibody to IL-6 had no effect onmyo-
tube diameter reduction caused by C26 CM (Fig. 3E). Further-
more, levels of IL-6 up to 2000 pg/ml are insufficient to stimulate
the STAT reporter or to cause myotube atrophy (Fig. 8).
Candidate LIF Target Genes in Myotubes—Quantitation of
increases in mRNAs in response to LIF treatment was per-
formed to identify potential LIF targets genes that could cause
the atrophy phenotype. Results from gene expression microar-
rays from RNA isolated at 4, 8, and 24 h after LIF treatment
served to guide the choice of qPCR candidates (see supplemen-
tary Tables S1 and S2 and GEO accession no. GSE68827). Pre-
viously identified STAT3 target genes found in other cell types
were up-regulated in myotubes treated with LIF (Socs3, Bcl3,
and C/EBP) (Fig. 9). These genes were also up-regulated in
muscle frommice with C26 tumors (21). Socs3, Bcl-3, C/EBP,
and Bnip3 were up-regulated at 4 h after a single LIF treatment
and subsided at later times, whereas Casp4 was increased sig-
nificantly at 24 h after LIF treatment (Fig. 9).
Discussion
Experiments have been performed to identify the factors that
trigger skeletalmuscle atrophy associatedwith cancer cachexia,
but treatment remains elusive. In this study, we used an in vitro
system consisting of the conditioned medium from C26 tumor
cells as a basis for a systematic study of the signaling pathways
in muscle. The model was found to simulate several character-
istics of cachexia observed inmice with C26 tumors (12, 13, 21)
when we evaluated C26 CMon differentiated C2C12myotubes
(not shown), surrogates for skeletal muscle in cachectic mice.
From our survey of transcription factor reporters, including
NF-B, C/EBP, FOXO, SMAD, AP-1, and STAT, we found that
C26CMactivates only the STAT reporter. This is in agreement
with others who have implicated STAT in the transcriptional
changes during C26 cancer cachexia (8, 12, 30), but it is the first
time that a STAT transcriptional assay has been used as evi-
dence. Subsequent to the finding that only STATwas activated
by C26 CM, we found, remarkably, that LIF is the cytokine
stimulating the JAK/STAT pathway in myotubes treated with
FIGURE 4. C26 CM and LIF effects on STAT activation. A, time course of STAT3 phosphorylation from 15min to 4 h after CM treatment (left panel) and LIF (6
ng/ml) treatment (right panel). B, time course of STAT1 phosphorylation from 15 min to 4 h after CM treatment (left panel) and LIF (6 ng/ml) treatment (right
panel). C, LIF antibody (Ab) inhibits C26 CM-induced STAT3 phosphorylation but not STAT1 phosphorylation. D, C26 CM induction of the STAT reporter is not
inhibited by PIAS1 but is attenuated by PIAS3. E, d.n.STAT3 expression attenuates the C26 CM- and LIF-induced (370 pg/ml) STAT reporter. F, Western blot of
pSTAT5 in C26 CM-treatedmyotubes 15min, 30min, 1 h, and 2 h after C26 CM treatment.G, d.n.STAT3 expression reverses C26 CM-inducedmyotube atrophy.
*, p 0.05 compared with control; †, p 0.05 compared with CM.
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medium from C26 cancer cells. The antibody to LIF was
uniquely able to block both STAT-dependent transcriptional
activation andmyotube atrophy because of C26 CM treatment.
Previously, LIF has been suggested as a candidate cachexia fac-
tor requiring further study (31). LIF is a known inhibitor of
lipoprotein lipase, an enzyme that affects adipose tissue and
whose inhibition results in the loss of body fat (32). Circulating
LIFwas found to be correlatedwith cachexiawhen expressed by
melanoma (31), and when purified LIF is injected in normal
mice, body fat is lost within 2 weeks (33). In our experiments,
we show that LIF originates from the C26 tumor and has a
direct atrophic effect on skeletal muscle. The requirement of
LIF also explains the loss of adipose tissue in C26 cancer
cachexia (7, 21).
The production of LIF appears to be widespread among
tumors. In one study of 17 human cancer cell lines, 12 were
found to secrete LIF (34). We measured LIF in medium from
other cancer cell lines described previously as LIF secretors (35,
FIGURE 5. JAK inhibitors block C26 CM- and LIF-induced STAT activation and atrophy. A, ruxolitinib (3 M) blocked STAT reporter induction by LIF (370
pg/ml) andC26CM. B, Western blot showing that ruxolitinib blocks C26CM-induced STAT3phosphorylation.C, ruxolitinib reversedC26CM-inducedmyotube
atrophy.D, ruxolitinib reversed LIF-inducedatrophy. E, C26CM inductionof STAT reporter is blockedby two JAK2 inhibitors, AG490 (5M) andWP1066 (10M).
*, p 0.05 compared with control; †, p 0.05 compared with CM or LIF.
FIGURE 6. ERK 1/2 in C26 CM and LIF-inducedmyotube atrophy. A, the ERK 1/2 inhibitor U0126 (3 M) blocks the atrophy produced by C26 CM. B, the ERK
1/2 inhibitor U0126 (3 M) blocks the atrophy produced by LIF (370 pg/ml). C, time course of the appearance of pERK 1/2 induced by C26 CM. D, U0126 does
not block STAT reporter induction by LIF or C26 CM. *, p 0.05 compared with control.
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36) and found it to be elevated. These were A172, 5637, and
Ehrlich cells (data not shown). In addition, conditioned
medium from these three cancer cell lines produced atrophy in
C2C12 myotubes, and the atrophy was blocked with a species-
specific antibody to LIF (data not shown). This suggests that LIF
is a cachectic factor in other tumor types besides C26.
LIF functions by activating at least two signaling pathways,
STAT and ERK (28). We found that these signaling pathways
are required for C26 CM and LIF-mediated myotube atrophy.
The STATpathway appears to have a component of STAT3but
not STAT1, which we discovered by differential inhibition of
these two molecules. Additional evidence for STAT3 and not
STAT1 is that a LIF-blocking antibody reversed the increased
phosphorylation of STAT3but not STAT1 inCM-treatedmyo-
tubes. Using selective JAK inhibitors, we determined that JAK2
is the signaling pathway activating STAT in our system. How-
ever, because JAK2 inhibition with AG490 and WP1066 can
abrogate STAT reporter activity but inhibitors of STAT3 are
only 50% effective in inhibition, it appears that some other
STAT species is also a part of the LIF-STAT reporter activation.
We have evidence that STAT5 shows signs of participation
because it is phosphorylated by C26 CM treatment. Therefore,
FIGURE 7. In vivo studies on LIF and STAT3 in C26 cancer cachexia. A, C26 tumor-induced fiber atrophy is reversed by expression of d.n.STAT3. B, photomi-
crograph of cross-sections of TAmuscles injected with d.n.STAT3. Red laminin staining outlines themyofibers, whereas green shows the location of d.n.STAT3
in nuclei. C, Western blot analysis of STAT3 and d.n.STAT3 stainedwith an antibody to STAT3. The d.n.STAT3 fusion protein is larger thanwild-type STAT3, also
shown in theblot. Theprotein loaded (40g)was fromTAmuscle injectedwith thed.n.STAT3plasmidor EGFPN1plasmid (Control plasmid).C, control.D, serum
LIF inmice with andwithout C26 tumors as a function of days of tumor inmice. E, serum IL-6 inmice with andwithout C26 tumors. F, serummyostatin inmice
with and without C26 tumors. G, C26 CM treatment of myotubes causes secretion of IL-6 into the medium, attenuated by LIF antibody (Ab). *, p  0.05
compared with control; †, p 0.05 compared with C26 CM.
FIGURE 8. IL-6 effects on C2C12myotubes. A, IL-6 at 10 ng/ml inducesmyotube atrophywhereas 2 ng/ml does not. B, With a 4-h incubation on 4-d differentiated
C2C12myotubes, the STAT reporter ismoderately activated by 10 and 100 ng/ml IL-6 but not at 2 ng/ml and lower. *, p 0.05 comparedwith control.
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the STAT signaling pathway is activated by LIF in C26 CM, and
interference with this pathway using a LIF antibody, JAK2
inhibitors, or STAT3 inhibition blocked atrophy in the C26 cell
culture model of myotube wasting. In addition, STAT3 inhibi-
tion blocked the muscle wasting associated with C26-induced
cancer cachexia.
ERK 1/2 is also required for both C26 CM and LIF-mediated
myotube atrophy, but it does not appear to be part of the STAT
response, and, therefore, we conclude that these two signaling
pathways are required in parallel to produce cachexia with this
tumor. Inmost cases, STAT and ERK are thought to work in par-
allelwhen inducedbyLIF (28).Previously,ERKinhibitionwasseen
to attenuate cachexia in C26 tumor in mice, although the mecha-
nism via LIF had not been determined at that time (11).
Treatment of myotubes with LIF confirms the elevation of sev-
eral genes already shown to be targets of STAT3, especially Socs3
and Bcl-3 and including C/EBP (37). The finding of C/EBP is
interesting because it has been linked to C26 cancer cachexia in a
recent paper (30). Increased expression of Bnip3 andCasp4 is also
suggestiveof theactivities that couldproduceatrophyofmyotubes
byLIF.Casp4,beingdelayedto24hfromLIFtreatment, appears to
be induced secondarily to the primary STAT3 targets. It remains
to be determined which of these genes contributes to the inhibi-
tion of atrophy when STAT3 is blocked.
The concentration of IL-6 in our C26 CM is quite low ( 10
pg/ml), but, in medium from myotubes treated with C26 CM,
IL-6 increased to 300pg/ml. However, this level of IL-6 was
unable to contribute to C26 CM-induced atrophy. IL-6 can
elicit atrophy in cell culture, but it requires a concentration of at
least 10 ng/ml and above (Fig. 8A) (12, 20), which is several
times more than found in sera from any reports on C26 tumors
(6, 8, 9, 38). The STAT reporter was induced moderately by
supraphysiological levels (10 and 100 ng/ml) of IL-6 but not at
the pathophysiological level of 2 ng/ml (Fig. 8B). In the litera-
ture, it has been shown that the serum level of IL-6 does not
correlate with cachexia in C26 cancer (39, 40). The sustained
injection of IL-6 alone intomice was not sufficient for inducing
cachexia (6, 9, 41) unless it is at supraphysiological levels (12,
42). The timing of the appearance of LIF and IL-6 in the sera
from our cachectic mice suggests that an increase in LIF pre-
cedes that of IL-6. The effect of LIF on IL-6 production was
shown by the blocking effect of anti-LIF on C26 CM-induced
FIGURE 9. LIF-induced gene expression in C2C12 myotubes. Quantitative RT-PCR measurement of selected mRNAs in myotubes 4, 8, and 24 h after LIF
treatment. Gene expression was normalized by two housekeeping genes (Gusb and Hprt). The gene expression -fold change is compared with untreated
controlmyotubes.A, Socs3. B, Bcl-3.C, C/EBP.D, Bnip3. E, Casp4. Geneswere selected formeasurement on the basis ofmicroarray data from the same starting
material (supplemental Tables S1 and S2). *, p 0.05 compared with time-matched control.
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IL-6 production by myotubes. Villiger et al. (43) have also
shown the ability of LIF to induce IL-6 in chondrocytes.
In a paper in which much work was described in muscle cell
culture with C26 conditionedmedium (10), myostatin has been
shown to be secreted by C26 cells, as determined by ELISA and
Western blots from the conditioned medium. In our work,
myostatin is not measureable from C26 tumor cells by either
ELISA orWestern blot except when serum is present in the cell
culture medium. Others have used myostatin to produce atro-
phy in C2C12myotubes, and it required 3–10g/ml (25), 1000
times as much as reported in C26 CM when it is found there
(10). In contrast, in normal mouse sera, we find high levels of
myostatin using the same ELISA that we used for the measure-
ment of myostatin in the C26 CM, and these in vivo levels cor-
respond to those reported previously (29). The levels of myo-
statin are then reduced significantly in the serum of mice with
advanced cachexia (Fig. 7F). Therefore, in our case, the atrophy
elicited by C26 cells in myotube cell culture and in skeletal
muscle in vivo appears to develop without myostatin being a
major factor.
Although FOXO is a transcription factor required for C26
tumor-inducedmuscle wasting (13), the lack of FOXO reporter
activation in our C26 CM-treated myotubes indicates that an
increase in FOXO activity does not play a primary role in the
induction of atrophy but, rather, that themaintenance of active
FOXO transcription is required for expression of the proteins
that carry out atrophy. In fact, we found that overexpression of
d.n.FOXO in myotubes treated with C26 CM blocks myotube
atrophy (data not shown).
Cachexia is a major complication of cancer, but it is a com-
plex pathology for which there are no known treatments. In this
study, onlySTAT-dependent transcriptionwas activatedof the six
transcription factor families tested, and this led us to the identifi-
cation of the gp130 cytokine LIF as the trigger of C26-induced
wastingof culturedmyotubesvia the JAK2-STAT3pathway.LIF is
present insecretions fromC26cells at levels thatproducemyotube
atrophy, andLIF is elevated in the serum fromC26 tumor-bearing
mice. LIF, JAK2, and STAT3 were all necessary for C26-induced
muscle wasting. Taken together, these data support an important
role of LIF-JAK2-STAT3 in the initiation and progression of C26
cancer cachexia and point to a therapeutic approach to treat some
types of cancer cachexia.
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